eNeura's SpringTMS® Migraine Treatment Receives Positive NICE Guidance

SUNNYVALE, Calif., Jan. 22, 2014 /PRNewswire/ -- eNeura Inc., a privately held medical technology company, announced today that the United Kingdom's National Institute for Health and Care Excellence (NICE) has published interventional procedure guidance recommending Transcranial Magnetic Stimulation (TMS) for the treatment of migraine. The new guidelines are based on a thorough technology appraisal, which includes assessments for product safety and efficacy for routine use, and are designed to support the National Health Service (NHS) in the process of introducing new procedures in a responsible way. 

eNeura's patented SpringTMS® device is the only portable single pulse TMS device clinically proven effective in the treatment of migraine. The device received CE marking in Europe for the acute treatment of migraine and is available by prescription in the UK. 

David K. Rosen, President and CEO of eNeura, commented, "NICE's independent, authoritative and evidence-based guidelines advise NHS on the most effective ways to prevent, diagnose and treat disease and ill health. The issuance of guidance regarding TMS for the treatment of migraine is an encouraging validation for our technology, as NHS will only consider routine use of any treatment with NICE guidance first being established.  In the UK alone, millions of people suffer from migraine, many without safe effective treatment options and we view NICE's guidance as a critical step in expanding the use of SpringTMS to reach this patient population."

SpringTMS is the only patient use TMS device available in the UK to treat migraine.  The user applies TMS to the back of the head using both hands and presses a button to generate a focused, single pulse of magnetic energy that treats the migraine headache non-invasively and without discomfort.

Professor Peter Goadsby, chair of the British Association for the Study of Headache, and director of the National Headache Centre at King's College Hospital in London, said, "Single pulse transcranial magnetic stimulation is a wonderful example of clinical and laboratory research delivering a real improvement in migraine treatment that is both effective and extremely well tolerated. Many patients are going to get real benefit from this device."

Consultant neurologist Dr. Fayyaz Ahmed, like Professor Goadsby a trustee of The Migraine Trust, said, "This is a breakthrough treatment for those who cannot tolerate or do not respond to current treatment, and opens the door for a new era in treating migraine headaches.  We welcome NICE guidance and very much hope this treatment is made available to those in need."

About eNeura
eNeura Inc., a privately held medical technology company, is pioneering the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for treatment of migraine.  Prescribed by physicians but designed for patient use, it is the first truly portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office or on the go.  The eNeura Spring TMS Total Migraine System device currently has CE marking in Europe and is available in the United Kingdom.  The company's first generation Cerena TMS device received clearance from the FDA for the treatment of migraine preceded by aura in December 2013.  For more information on eNeura and TMS please visit http://www.eneura.com.

Media Contacts:
Jason Rando / Claire Sojda
Tiberend Strategic Advisors, Inc.
212.827.0020
[email protected] 
[email protected]

SOURCE eNeura Inc.